MediMix aims to bring high value medical information to Belgian healthcare professionals via multiple channels. Our team covers congresses and symposia all over the world, particularly in the oncology domain. In collaboration with Belgian and international experts, we bring the newest data to Belgian physicians.
Two clinical trials were conducted to assess the role of radiotherapy in the treatment of locally advanced rectal cancer. In the CONVERT trial, neoadjuvant chemotherapy (nCT) with CAPOX alone was
Two investigations were presented concerning RAS-wildtype unresectable metastatic colon cancer, employing FOLFOXIRI treatment paired with the antibody therapy cetuximab.
The first, TRICE, was a randomized clinical trial comparing the chemotherapy
MediMix is introducing “What’s New Doc in Breast Cancer?” – a weekly update on the latest research in breast cancer.
Dr Kevin Punie from GZA Ziekenhuizen, Antwerp, and Prof Evandro De Azambuja from the Jules Bordet Institute, Brussels, will provide you with detailed information on the latest data and offer you fresh insights into breast cancer treatment and research.
“What’s New Doc in Breast Cancer?” is just the beginning – it will soon expand into other domains such as GI, lung, gynaecological tumours and more. Stay tuned for a diverse range of cutting-edge communication.